Answers are grounded in this paper and cite their sources.
Background: Age-related macular degeneration (AMD) is a leading cause of irreversible visual impairment in older adults. Its clinical spectrum extends from drusen and pigmentary abnormalities to geographic atrophy (GA) and macular neovascularization (MNV). Rapid advances in retinal imaging and treatment have improved risk stratification and vision preservation, but they have also created new questions about biomarker interpretation, treatment burden, and the clinical value of emerging therapies.Objective: To synthesize contemporary evidence on AMD classification, multimodal diagnosis, imaging biomarkers, established management, and emerging treatments, with emphasis on findings that change clinical decisions.Methods: A targeted narrative synthesis was performed using an author-supplied dossier of 50 English-language records and the corresponding accessible full texts. Forty-five publications were eligible because they were present in the dossier, available in full text, and directly relevant to AMD diagnosis, prognosis, or therapy. Five records without an available full text were excluded. Evidence was organized by clinical stage and decision point; no meta-analysis was undertaken.Results: Structural optical coherence tomography (OCT) is the central modality for staging, detecting exudation, and guiding anti-vascular endothelial growth factor (anti-VEGF) treatment. External limiting membrane, ellipsoid-zone, and interdigitation-zone abnormalities, intraretinal hyperreflective foci, hyporeflective drusen cores, and reticular pseudodrusen refine progression risk beyond drusen size alone. OCT angiography can identify nonexudative MNV, but current evidence supports closer surveillance rather than prophylactic treatment. Anti-VEGF therapy remains the standard for neovascular AMD, and proactive individualized regimens can reduce visits and injections while preserving visual outcomes in selected patients. AREDS2-type supplementation benefits appropriate higher-risk non-neovascular AMD but does not treat established late disease. Complement inhibitors modestly slow GA enlargement without restoring vision and increase treatment burden; conversion to exudative MNV requires surveillance. Gene therapy and photobiomodulation are promising but remain less mature than established care.Conclusions: Modern AMD care should combine standardized staging, OCT-centered multimodal imaging, risk-factor modification, stage-specific therapy, and explicit shared decision-making. Imaging biomarkers are most useful when they trigger a defined action, while emerging treatments should be discussed in terms of absolute benefit, procedural burden, safety, and uncertainty.
No takes yet. Share an insight, caveat, or question.
Jadov et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: